A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part. (divided in two parts: Part A \[OC and EC participants\] and Part B \[OC only\]): Part A: to evaluate other farletuzumab ecteribulin (MORAb-202) treatment regimens for safety, tolerability and preliminary efficacy in participants with OC and EC; to evaluate the addition of short course of oral corticosteroids following every dose of farletuzumab ecteribulin (MORAb-202) administered every 21 days; and to select treatment regimens with farletuzumab ecteribulin (MORAb-202) for further evaluation in Part B. Part B: to evaluate the safety and tolerability of different doses of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib and to determine the recommended dose (RD) of farletuzumab ecteribulin (MORAb-202) as monotherapy and in combination with lenvatinib.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony histologicznie rak piersi potrójnie ujemny (TNBC) w stadium rozsiewu, już leczony co najmniej jedną linią terapii
- •Potwierdzony histologicznie lub cytologicznie rak płuca typu gruczolakowatego w stadium rozsiewu, niepoddający się standardowym terapiom
- •Potwierdzony histologicznie zaawansowany, nawrotowy lub rozsiewowy rak endometrium, oporny na wcześniejszą chemioterapię lub immunoterapię
- •Potwierdzony histologicznie wysoko złośliwy rak jajnika, rak otrzewnej lub rak jajowodu w stadium rozsiewu
- •Oporność na platynę: progresja nowotworu w ciągu 6 miesięcy od ostatniej dawki chemii zawierającej platynę
- •Otrzymanie do 4 linii terapii systemowej po stwierdzeniu oporności na platynę
- •Kobiety (dla raka piersi, endometrium, jajnika) lub kobiety i mężczyźni (dla raka płuca)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (58)
ACRC/Arizona Clinical Research Center, Inc
Tucson, United States
Universty of Arkansas for Medical Sciences
Little Rock, United States
Stanford Women's Cancer Center
Palo Alto, United States
University of Miami
Coral Gables, United States
Moffitt Cancer Center and Research Institute
Tampa, United States
Winship Cancer Institute
Atlanta, United States
Georgia Cancer Center
Augusta, United States
Northwestern Memorial Hospital
Chicago, United States
Ascension Illinois-Skokie Infustion Center
Skokie, United States
Norton Healthcare
Louisville, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, United States
Karmanos Cancer Institute
Detroit, United States
Henry Ford Hospital
Detroit, United States
MD Anderson Cancer Center at Cooper
Camden, United States
Columbia University Medical Center
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
University of Cincinnati Medical Center
Cincinnati, United States
OSU Wxner Medical Center
Hilliard, United States
Oregon Health & Science University
Portland, United States
Medical University of South Carolina
Charleston, United States
Chattanooga's Program in Women's Oncology
Chattanooga, United States
Vanderbilt University Medical Center
Nashville, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
University of Virginia Comprehensive Cancer Center
Charlottesville, United States
Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer
Nice, France
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, France
Institut Paoli Calmettes
Marseille, France
Hopitaux de La Timone
Marseille, France
Centre François Baclesse
Caen, France
Clinique Armoricaine de Radiologie-PPDS
Saint-Brieuc, France
EDOG Institut de Cancerologie de l'Ouest
Nantes, France
Clinique Catherine de Sienne
Nantes, France
Centre Oscar Lambret
Lille, France
Centre Hospitalier de La Côte Basque
Bayonne, France
Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
Lyon, France
CLCC-Gustave Roussy Cancer
Vilejuif, France
Hôpital de la Croix Saint-Simon
Paris, France
Hopital Cochin
Paris, France
National Cancer Center Hospital
Chuo-ku, Japan
Cancer Institute Hospital of JFCR
Koto-ku, Japan
ICO Badalona-H.U. Germans Trias i Pujol
Badalona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Clinica Universidad de Navarra
Madrid, Spain
Hospital Clinico San Carlos
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitario de Toledo
Toledo, Spain
Fundacion Instituto Valenciano de Oncologia
Valencia, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Belfast City Hospital
Belfast, United Kingdom
Beatson West of Scotland Cancer Centre-PPDS
Glasgow, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Lancashire Clinical Research Facility, Royal Preston Hospital
Preston, United Kingdom
Guy's and St Thomas's Hospital
London, United Kingdom
Mount Vernon Cancer Centre
Northwood, United Kingdom
Velindre Cancer Centre-PPDS
Cardiff, United Kingdom
The Royal Marsden in Sutton
Sutton, United Kingdom
Trial contact
Eisai Medical Information
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.